Drugs / KSP-QRH-E3-IRDye800
KSP-QRH-E3-IRDye800
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03643068 | Aug → Oct 2018 | — | University of Michigan | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSP-QRH-E3-IRDye800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03643068 ↗ |
| Known as | KSP/QRH Dimer | “To evaluate the safety of orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G), a topically administered Li-Cor IRDye800CW labeled heptapeptide dimer (KSP/QRH Dimer)...” NCT03643068 ↗ |
| Known as | Peptide 919288G | “To evaluate the safety of orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G), a topically administered Li-Cor IRDye800CW labeled heptapeptide dimer (KSP/QRH Dimer)...” NCT03643068 ↗ |
| Modality | Peptide | “a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence” NCT03643068 ↗ |
| Route | Oral | “orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G)” NCT03643068 ↗ |
| Target | HER2 | “specific for human epithelial growth factor receptor 2 (HER2)” NCT03643068 ↗ |